Genomic Determinants of Clinical Outcomes in Rhabdomyosarcoma.

CONCLUSION: High TMB was associated with worse clinical outcomes in patients with RMS. With further validation, TMB and other genomic classifiers may be combined with traditional clinicopathologic risk factors to guide risk stratification and ultimately treatment decisions. PMID: 31699828 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31699828?dopt=Abstract

Source: Clinical Cancer Research - November 6, 2019 Category: Cancer & Oncology Authors: Casey DL, Wexler LH, Pitter KL, Samstein RM, Slotkin EK, Wolden SL Tags: Clin Cancer Res Source Type: research